References
- SiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin201565152925559415
- ChenWZhengRBaadePDCancer statistics in China, 2015CA Cancer J Clin201666211513226808342
- ZhouBZhanHTinLTUFT1 regulates metastasis of pancreatic cancer through HIF1-Snail pathway induced epithelial-mesenchymal transitionCancer Lett20163821112027566398
- KaderaBETostePAWuNLow expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibitionClin Cancer Res201521115716525348515
- DelittoDPerezCHanSDownstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancerCancer Immunol Immunother201564121553156326423423
- XiaoGDengALiuHGeGLiuXActivator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1Proc Natl Acad Sci U S A201210938154191542422949674
- TassiEGraziaGVegettiCEarly effector T lymphocytes coexpress multiple inhibitory receptors in primary non-small cell lung cancerCancer Res201777485186127979840
- ChatterjeeJDaiWAzizNHAClinical use of programmed cell death-1 and its ligand expression as discriminatory and predictive markers in ovarian cancerClin Cancer Res201731334533460
- DaleyDZambirinisCPSeifertLGammadelta T cells support pancreatic oncogenesis by restraining alphabeta T cell activationCell2016166614851499.e141527569912
- IraolagoitiaXLSpallanzaniRGTorresNINK cells restrain spontaneous antitumor CD8+ T cell priming through PD-1/PD-L1 interactions with dendritic cellsJ Immunol (Baltimore, Md: 1950)20161973953961
- ShaabaniNDuhanVKhairnarVCD169+ macrophages regulate PD-L1 expression via type I interferon and thereby prevent severe immunopathology after LCMV infectionCell Death Dis2016711e244627809306
- LiZDongPRenMPD-L1 expression is associated with tumor FOXP3(+) regulatory T-cell infiltration of breast cancer and poor prognosis of patientJ Cancer20167778479327162536
- HendriksDHeYKoopmansIProgrammed death ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis inductionOncoimmunology201658e120239027622071
- OhigashiYShoMYamadaYClinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancerClin Cancer Res20051182947295315837746
- ChenJLiGMengHUpregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomasCancer Immunol Immunother201261110110821853301
- KimJHParkHEChoNYLeeHSKangGHCharacterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancersBr J Cancer2016115449049627404452
- MuenstSSchaerliARGaoFExpression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancerBreast Cancer Res Treat20141461152424842267
- LiuYCarlssonRAmbjornMPD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patientsJ Neurosci20133335142311424523986257
- CooperWATranTVilainREPD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinomaLung Cancer (Amsterdam, Netherlands)2015892181188
- BogerCBehrensHMMathiakMKrugerSKalthoffHRockenCPD-L1 is an independent prognostic predictor in gastric cancer of Western patientsOncotarget2016717242692428327009855
- WellsGSheaBO’ConnellDThe Newcastle-Ottawa Scale (nos) for assessing the quality of nonrandomised studies in meta-analysesOttawa Hospital Research Institute Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.aspAccessed March 28, 2017
- TierneyJFStewartLAGhersiDBurdettSSydesMRPractical methods for incorporating summary time-to-event data into meta-analysisTrials2007811617555582
- BirnbaumDJFinettiPLoprestiAPrognostic value of PDL1 expression in pancreatic cancerOncotarget2016744711987121027589570
- DianaAWangLMD’CostaZPrognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinomaOncotarget2016727409924100427329602
- YamakiSYanagimotoHTsutaKRyotaHKonMPD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8+ tumor-infiltrating lymphocytes: highly sensitive detection using phosphor-integrated dot stainingInt J Clin Oncol201724726733
- WangYLinJCuiJPrognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancerOncotarget2017869354936528030840
- ChenYSunJZhaoHThe coexpression and clinical significance of costimulatory molecules B7-H1, B7-H3, and B7-H4 in human pancreatic cancerOnco Targets Ther201471465147225170273
- LiuJWLuYShenGJYaoWFHuangDSThe relationship of B7-H1 with clinicopathologic characteristics and prognosis of pancreatic carcinomaChin J Gen Pract2016144571574
- LoosMGieseNAKleeffJClinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancerCancer Lett200826819810918486325
- NomiTShoMAkahoriTClinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancerClin Cancer Res20071372151215717404099
- WangLMaQChenXGuoKLiJZhangMClinical significance of B7-H1 and B7-1 expressions in pancreatic carcinomaWorld J Surg20103451059106520145927
- ChuDDChuZHZhangJLClinical significance of PTEN and B7-H1 expressions in pancreatic carcinomaChin J Exp Surg2011285723726
- SongXLiuJLuYJinHHuangDOverexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancerOncol Rep20143131191119824378899
- InamuraKYokouchiYSakakibaraRRelationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinomaJpn J Clin Oncol2016461093594127511990
- WuPWuDLiLChaiYHuangJPD-L1 and survival in solid tumors: a meta-analysisPLoS One2015106e013140326114883
- DaiCWangMLuJPrognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysisOnco Targets Ther2017103625363428769571
- AlexandrovLBJuYSHaaseKMutational signatures associated with tobacco smoking in human cancerScience (New York, NY)20163546312618622
- MaisonneuvePLowenfelsABRisk factors for pancreatic cancer: a summary review of meta-analytical studiesInt J Epidemiol201544118619825502106
- YadavDLowenfelsABThe epidemiology of pancreatitis and pancreatic cancerGastroenterology201314461252126123622135
- LinYMSungWWHsiehMJHigh PD-L1 expression correlates with metastasis and poor prognosis in oral squamous cell carcinomaPLoS One20151011e014265626562534
- MoriSMotoiNNinomiyaHHigh expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor casesPathol Int2017671374427976463
- InamuraKYokouchiYKobayashiMTumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosisLung Cancer (Amsterdam, Netherlands)20171034451
- AbikoKMatsumuraNHamanishiJIFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancerBr J Cancer201511291501150925867264
- QuandtDJasinski-BergnerSMullerUSchulzeBSeligerBSynergistic effects of IL-4 and TNFalpha on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferationJ Transl Med201412115124885059
- Rodriguez-GarciaMPorichisFde JongOGExpression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10J Leukoc Biol201189450751521097698
- FukudaTKamaiTMasudaAHigher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinomaCancer Med2016581810182027292320
- KronigHKremmlerLHallerBInterferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatmentEur J Haematol201492319520324175978
- ChenNFangWZhanJUpregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutationJ Thorac Oncol201510691092325658629
- OtaKAzumaKKawaharaAInduction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancerClin Cancer Res201521174014402126019170
- SoaresKCRuckiAAWuAAPD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumorsJ Immunother (Hagerstown, Md: 1997)2015381111
- WilkeCMWeiSWangLKryczekIKaoJZouWDual biological effects of the cytokines interleukin-10 and interferon-gammaCancer Immunol Immunother201160111529154121918895
- IrelandLSantosAAhmedMSChemoresistance in pancreatic cancer is driven by stroma-derived insulin-like growth factorsCancer Res201676236851686327742686
- YangSHGuoJCYehKHTienYWChengALKuoSHAssociation of radiotherapy with favorable prognosis in daily clinical practice for treatment of locally advanced and metastatic pancreatic cancerJ Gastroenterol Hepatol201631122004201227059987
- AzadAYin LimSD’CostaZPD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapyEMBO Mol Med20179216718027932443
- GibsonAOgeseMSullivanANegative regulation by PD-L1 during drug-specific priming of IL-22-secreting T cells and the influence of PD-1 on effector T cell functionJ Immunol (Baltimore, Md: 1950)2014192626112621
- MaceTAShakyaRPitarresiJRIL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancerGut Epub20161021
- AntoniaSGoldbergSBBalmanoukianASafety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b studyLancet Oncol201617329930826858122
- BassoDFogarPFalconiMPancreatic tumors and immature immunosuppressive myeloid cells in blood and spleen: role of inhibitory co-stimulatory molecules PDL1 and CTLA4. An in vivo and in vitro studyPLoS One201381e5482423359812